Posts Tagged ‘high risk prostate cancer’

NEW PROSTATE CANCER INFOLINK: “Are we over-treating 50,000 men each year? Could it be even more?” asks Mike Scott, the sitemaster of America’s leading prostate cancer discussion website.

These questions begin his analysis of an article by Welch and Albertsen in this week’s issue of the Journal of the National Cancer Institute, which estimates how much “over-treatment” may have occurred during the 20-year period from 1986 and 2005. READ MORE>

It is their belief that it is of the order of 1 million men (an average of about 50,000 per year) or higher — and we have no reason to disagree with them.

Later, Mike writes:

If we can’t come up with a better way to differentiate between high risk and indolent prostate cancer (and quickly), then we need to come up with a better way to manage prostate cancer based on the information currently available.

The academic discussion is of intellectual interest, but is not a basis for clinical decision making.

We need a way to help men and their doctors make the right decision about management once a diagnosis is made (as opposed to telling them that diagnosing prostate cancer may be  the wrong thing to do).

Read Full Post »

JULY 31: URO TODAY: Researchers have investigated whether whole-pelvis radiotherapy in combination with interstitial brachytherapy – thus covering the pelvic lymph nodes – improves treatment outcome in high-risk prostate cancer. READ MORE>

Read Full Post »

JULY 27: URO TODAY: A combination approach to hormone and radiation treatment for men with localised but high risk prostate cancer works better than so-called mono-therapy, a new study has found. READ MORE>

Men treated with external beam radiotherapy and brachytherapy, short-course androgen suppression therapy with a luteinizing hormone-releasing hormone (LHRH) agonist plus an anti-androgen, have decreased prostate cancer-specific mortality compared with mono-therapy with an LHRH agonist, the researchers report.

NEW PROSTATE CANCER INFOLINK: Another study (of about 200 patients) in Japan found combined androgen blockade with an LHRH) agonist + bicalutamide 80 mg had a small, marginally significant overall survival benefit compared to an LHRH agonist + a placebo (ie, LHRH agonist monotherapy) at a median follow-up of 5.2 years. READ MORE>

Read Full Post »

JUNE 5: NEW PROSTATE CANCER INFO-LINK: German researchers conclude that adjuvant radio therapy for patients with high risk prostate cancer and  post-operatively undetectable PSA significantly reduces the risk of biochemical progression, but also note that further follow-up is needed to assess the effect on metastases-free and overall survival. READ MORE>

Read Full Post »